Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN63,7463,980,88
Msft2,15
Nokia4,14254,185,37
IBM0,41
Daimler AG37,72537,7453,14
PFE0,00
07.07.2020 1:37:40
Indexy online
AD Index online
select
AD Index online
 

Roche Holding AG
Poslední obchod Změna (%) Změna Objem obchodů ()
- - -
Poslední obchod Změna (%) Změna Objem obchodů ()
- - -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 07.07.2020
Popis společnosti
Obecné informace
Název společnostiRoche Holding AG
TickerROG
TickerRO
Kmenové akcie:Genussscheine
Kmenové akcie:Ordinary Shares
RICRO.S
RICROG.S
ISINCH0012032048
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky31.03.2020
Počet zaměstnanců k 31.12.2019 97 735
Akcie v oběhu k 31.12.2019 855 756 455
MěnaCHF
Kontaktní informace
UliceGrenzacherstr. 124
MěstoBASEL
PSČ4058
ZeměSwitzerland
Kontatní osobaKarl Mahler
Funkce kontaktní osobyHead of Investor Relations
Telefon419 732 354 295

Business Summary: Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2019, Roche Holding AG revenues increased 8% to SF61.47B. Net income before extraordinary items increased 29% to SF13.5B. Revenues reflect Diagnostics segment increase of 1% to SF12.95B, United States segment increase of 14% to SF29.72B, Rest of Asia segment increase of 13% to SF8.7B, Japan segment increase of 9% to SF4.55B. Dividend per share increased from SF8.70 to SF9.00.
Odvětvová klasifikace
TRBC2012Pharmaceuticals - NEC
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYMajor Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSInVitro Diagnostic Substance Manufacturing
NAICSAnalytical Laboratory Instrument Manufacturing
NAICSSurgical Appliance and Supplies Manufacturing
NAICSSurgical and Medical Instrument Manufacturing
NAICSMedicinal and Botanical Manufacturing
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
NAICSOffices of Other Holding Companies
SICPharmaceutical Preparations
SICBiological Prod's Not Diagnostic
SICDiagnostic Substances
SICAnalytical Instruments
SICSurgical Appliances And Supplies
SICSurgical And Medical Instruments
SICMedicinals And Botanicals
SICElectromedical Equipment
SICHolding Companies, Nec



  • Poslední aktualizace: 07.07.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Corporate Executive Committee, Chief Executive Officer, Executive DirectorSeverin Schwan5301.01.2006
Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology OfficerAlan Hippe5301.04.201101.04.2011
Member of the Corporate Executive Committee, Head Group Human ResourcesCristina Wilbur53
Chief Compliance OfficerPascale Schmidt-01.10.201901.10.2019
Member of the Corporate Executive Committee, General CounselClaudia Boeckstiegel5501.04.202001.04.2020
Member of the Corporate Executive Committee, Chief Executive Officer Roche PharmaceuticalsWilliam Anderson5301.01.201901.01.2019
Member of the Enlarged Corporate Executive Committee, Head Roche Pharma Research & Early Development (pRED)William Pao5302.04.201802.04.2018
Member of the Enlarged Corporate Executive Committee, Global Head Pharma PartneringJames Sabry6101.08.201801.08.2018
Member of the Enlarged Corporate Executive Committee, Head Group CommunicationsBarbara Schaedler5801.10.201901.10.2019
Member of the Corporate Executive Committee, Chief Executive Officer Roche DiagnosticsThomas Schinecker4501.08.201901.08.2019